DuBiner and Hubatsch BMC Ophthalmology 2014, 14:151 http://www.biomedcentral.com/1471-2415/14/151
RESEARCH ARTICLE
Open Access
Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial Harvey B DuBiner1* and Douglas A Hubatsch2
Abstract Background: Medications to control intraocular pressure (IOP) are frequently preserved using benzalkonium chloride (BAK), which can negatively affect the ocular surface. Data are needed to assess efficacy and safety of prostaglandin drugs preserved with and without BAK. The present study compared the efficacy and safety of BAK-free travoprost 0.004% (TRAV) and BAK 0.02%–preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension. Methods: This was a 12-week, phase 4, randomized, investigator-masked, crossover study. 84 patients with IOP ≥24 and
